BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma (NCT03264131), a na phase 2 study. The primary outcome is Complete Response Rate After 2-6 Cycles of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP).

2. Clinical Question

The study asks whether complete responses were observed after treatment with brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone, a combination called BV-CHEP, in participants with adult T-cell leukemia/lymphoma. The primary endpoint was the count of participants with a complete response after 2-6 cycles, assessed at 18 weeks. Response assessment followed the Lugano criteria described in the registry record.

The question is therefore about the observed response experience in a small, single-group study, rather than a direct estimate of the difference between treatments. Without a reported response count and denominator, the response proportion and its precision cannot be described from the registry record. The study also lists secondary questions about overall response, progression-free survival, duration of response, overall survival, and adverse events; results for those outcomes are not included in the registry record reported for this analysis.

3. Trial Design

The registry describes a Phase 2, open-label, multicenter, single-arm pilot study sponsored by UNC Lineberger Comprehensive Cancer Center. The study is marked completed, with enrollment listed as 16. Its start date is 2018-10-11 and its primary completion date is 2023-12-15. No allocation to multiple treatment groups is described; the allocation entry is NA, consistent with the stated single-group model.

Participants received concurrent brentuximab vedotin and CHEP: cyclophosphamide, doxorubicin, etoposide, and prednisone. The primary endpoint concerns complete response after 2-6 cycles, assessed at 18 weeks. The registry describes response assessment using the Lugano criteria. The intervention description includes treatment schedule details, but the available record excerpt is incomplete, so those details are not used to characterize the full regimen.

A single-arm design can describe outcomes observed among participants receiving the study regimen. It does not, on its own, establish how those outcomes compare with what would have occurred under another treatment or under no study treatment. Because there is no concurrent control arm, changes over time or differences from other patient groups cannot be attributed to the regimen using a randomized comparison in this study.

The registry record does not report a sample-size justification, a prespecified statistical analysis plan, interim analyses, or details of how participants were selected for analysis. These omissions matter when interpreting a pilot study: the enrollment count alone does not establish the precision intended for the primary estimate, and a completed status does not indicate what the endpoint results were. The primary response count and corresponding uncertainty are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: A total of sixteen eligible participants consented and started to the study.

Overall Study

Analysis population for the primary outcome, as defined in the registry: Participants started the study and response assessments were completed.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Participants consented and started the study.

6. Primary Endpoint

The registry lists the primary outcome as Complete Response Rate After 2-6 Cycles of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (BV-CHEP), measured over 18 weeks.

The primary endpoint is the count of participants with a complete response after 2-6 cycles of BV-CHEP. The registry gives an assessment timeframe of 18 weeks and says response was evaluated using the Lugano criteria. Those criteria use imaging findings from positron emission tomography (PET) and computerized tomography (CT). In broad terms, they distinguish complete response from partial response, stable or no response, and progressive disease according to metabolic activity and changes in measurable disease.

This endpoint is used to describe whether participants met a defined response category after treatment. A response category based on common criteria can make assessments more consistent than an undefined judgment, but the endpoint still depends on the assessments being completed and interpreted according to those criteria. The registry describes the primary measure as a participant count, not as a time-to-event outcome.

The population description refers to participants who started the study and completed response assessments. The number of participants meeting that description, the number with complete response, and the response proportion are not reported in the registry record. Therefore, the endpoint definition can be explained, but the observed primary result and its precision cannot be assessed from the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Because the primary endpoint is a participant count, the basic statistical description would ordinarily include the number meeting the complete response definition and the number assessed. A proportion could then summarize the response frequency in the analyzed group. In general, a confidence interval around a proportion expresses uncertainty due to sampling variation: a wider interval indicates less precision, while a narrower interval indicates greater precision under the method used. The registry record does not report the primary count, denominator, proportion, or confidence interval, so none can be described for this study.

What does a single-arm design estimate?

In a single-arm study, outcomes are observed in participants receiving the study intervention. The resulting estimate describes that group under the study’s eligibility criteria, treatment delivery, and assessment process. It does not provide a direct randomized comparison with another treatment. Differences between the observed group and an external group could reflect differences in participant characteristics, care, follow-up, or outcome measurement, rather than a treatment effect. General statistical interpretation therefore separates a group’s observed outcome from a comparative causal estimate.

Here, the registry calls the study single-arm and open-label, and the allocation entry is NA. There is no control-arm outcome in the record details. The primary response result itself is also absent. Those features prevent a treatment contrast from being estimated from the registry information.

Why does the response definition matter?

A binary response endpoint classifies each assessed participant according to whether the defined condition is met. In this study, the definition refers to the Lugano criteria and PET and CT findings. Standardized criteria can reduce ambiguity by specifying how imaging findings map to response categories. Even so, the result depends on the availability and interpretation of assessments. General measurement principles make clear that incomplete assessments or differing interpretation can affect which participants are classified as complete responders.

The endpoint population is described as participants who started the study and completed response assessments. The registry record does not report how many participants completed those assessments or how missing assessments were handled. It is therefore not possible to determine whether the reported enrollment entry and the endpoint analysis population would be the same.

What can the sample-size illustrations say?

Planning illustrations based on an observed effect are not the same as observed trial outcomes. In general, such calculations explore how many participants might be needed under specified assumptions to detect a chosen effect at a stated significance level and power. Their results depend on the assumed effect, allocation, statistical approximation, and endpoint type. They do not show that a study had a particular probability of finding a result after it was conducted. They are not observed power.

The registry record does not report a sample-size justification or the trial’s own statistical planning assumptions. Any planning illustrations associated with an observed effect should therefore be read as hypothetical design calculations, not as evidence that the study was adequately powered or as a substitute for the missing endpoint result. The registry record also does not report a primary analysis plan that would establish the intended method for the endpoint.

What do adverse-event counts represent?

Adverse-event summaries describe participants with reported events in a defined safety group. They do not, without further detail, describe event duration, severity beyond the specified category, timing, recurrence, or causal attribution. The registry lists 7 participants affected by serious adverse events among 16 at risk and 9 affected by other adverse events among 16 at risk. These are participant counts, not a comparative estimate against another group. The adverse-event summary lists 12 deaths, but the information does not report their causes, timing, or relationship to treatment.

General statistical interpretation also distinguishes the number of participants with at least one event from the total number of event occurrences. The summary values are participant-based affected counts; they should not be read as a complete account of event frequency or burden. The registry record does not provide exposure-adjusted event rates in the details used for this analysis.

What remains unavailable?

The registry record reports no analysis entries. It does not report the primary response estimate, statistical uncertainty, p-value, analysis population details, or missing-data method. It also does not report an interim analysis plan, multiplicity adjustment, or detailed statistical model. These are not details that can be reconstructed from the endpoint definition or from the enrollment entry. Without them, interpretation should remain descriptive and should not imply a prespecified analysis that is not reported.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists multiple outcomes, including overall response, progression-free survival, duration of response, overall survival, adverse events, and progression-free survival for maintenance therapy. When several outcomes or statistical tests are examined, general statistical practice considers multiplicity: the chance of at least one apparently notable result can increase as more tests are conducted. Methods such as prespecifying a primary outcome or adjusting for multiple comparisons can address particular multiplicity concerns. The registry record does not report whether a multiplicity strategy was planned or used.

The primary endpoint is identified as complete response after 2-6 cycles. However, the statistical analysis plan, testing hierarchy, and any adjustment for secondary analyses are not reported in the registry record. The outcome list alone does not establish which results were confirmatory or how they were interpreted.

The endpoint population is described as participants who started the study and completed response assessments. The number in that population and the handling of participants without a completed assessment are not reported in the registry record. No missing-data method, imputation approach, or sensitivity analysis is reported. The record also does not specify an intention-to-treat, per-protocol, or other named analysis population. These omissions limit assessment of whether exclusions or incomplete follow-up could influence the endpoint estimate.

Because the primary response count and denominator are absent, the effect of missing assessments cannot be evaluated. The listed enrollment and the safety-group counts do not fill that gap. Interpretation should therefore distinguish the stated endpoint definition from the unreported analysis population and analysis methods.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: febrile neutropenia (12.5%), general disorders and administration site conditions - other, specify (12.5%), infections and infestations - other, specify (12.5%), hearing impaired (6.2%), eye pain (6.2%).

The adverse-event summary lists 7 participants with serious adverse events among 16 at risk and 9 participants with other adverse events among 16 at risk in the single study group. These figures count participants affected; they do not indicate the total number of event occurrences, the duration of events, or the risk relative to a control group. The study has no comparator arm, so the registry summary does not support a direct between-treatment safety comparison.

The registry also lists 12 deaths. Their timing, causes, and relationship to treatment are not reported in the registry record details. A death count alone cannot establish whether deaths were treatment-related or whether the reported events preceded or followed a particular assessment.

Among the serious-event terms listed, febrile neutropenia, general disorders and administration site conditions - Other, specify, and infections and infestations - Other, specify each have 12.5%. Hearing impaired, eye pain, and constipation each have 6.2%. These are the percentages as recorded; the summary does not establish the clinical course or causal attribution for each term. The listed terms should be read as reported categories, not as a complete account of every safety outcome or as evidence of comparative risk.

12. What the Result Does, and Does Not, Mean

The record describes a completed Phase 2 pilot study of BV-CHEP in adult T-cell leukemia/lymphoma, with enrollment listed as 16. It specifies a complete response endpoint after 2-6 cycles, an 18-week assessment timeframe, and use of the Lugano criteria. These details identify what the study intended to measure and how its primary response category was defined.

The record does not report the number of complete responses, the analyzed denominator, a response proportion, or statistical uncertainty for the primary endpoint. It therefore does not show the observed primary response result. Completion status cannot substitute for an outcome result, and the endpoint definition cannot be treated as evidence that participants did or did not respond.

The single-arm design also means that the study does not provide a randomized comparison with another treatment. Even if an outcome estimate were available, it would describe the study group rather than establish a causal difference against a control arm. The record’s adverse-event counts offer a safety description for the study group, but they do not provide comparative risk estimates or establish that events were caused by the regimen.

In general, a small study may provide descriptive evidence while leaving substantial uncertainty about the frequency of outcomes in a wider population. The degree of uncertainty is normally judged from the estimate, denominator, and interval, not from the enrollment entry alone. Since the primary estimate and interval are not reported in the registry record, the precision of the response result cannot be assessed.

The responsible reading is therefore narrow: the registry defines a study, intervention, endpoint, assessment criteria, and selected safety summaries, but the primary response result and several analysis details are not reported. No claim about efficacy, comparative benefit, or treatment-related harm follows from these design details alone.

13. Why This Trial Matters Statistically

This study is statistically notable for the challenges of interpreting a small, single-arm pilot in a rare disease setting. The registry describes adult T-cell leukemia/lymphoma as the study condition and lists enrollment of 16. A single-group study can document what was observed among enrolled participants, but the absence of a concurrent control limits comparative interpretation. That distinction is important whenever an observed outcome might otherwise be mistaken for an estimate of treatment effect.

The endpoint is defined using a response framework that distinguishes complete response from other response categories based on PET and CT findings. Clear definitions are central to reproducible measurement, especially when outcomes depend on imaging assessment. At the same time, a well-defined endpoint does not answer the statistical question unless the observed count, analysis denominator, and uncertainty are also reported.

The registry record illustrates why study status, enrollment, and outcome reporting should be considered separately. The study is marked completed, but the primary response count and its precision are not reported in the record details. Completion establishes a status designation; it does not establish the magnitude or certainty of an outcome.

Safety summaries also require careful interpretation. Participant counts and listed event terms can describe reported experience, but they do not provide a controlled comparison or explain event timing and attribution. In a single-arm study, separating descriptive safety reporting from causal claims is especially important.

Finally, the presence of several secondary outcomes raises questions about analysis planning and multiplicity, while the registry record does not report the relevant statistical plan. The case underscores a general principle: design and endpoint definitions are necessary for interpretation, but transparent reporting of results, populations, and methods is also needed to judge statistical evidence.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting the primary endpoint is that the registry record does not report its observed result. The complete response count, analysis denominator, response proportion, and confidence interval are unavailable in the record details. Enrollment is listed as 16, but the primary endpoint population is defined by study start and completed response assessments, and its size is not reported.

The single-arm, open-label design has no concurrent control group. It cannot provide a randomized comparison, and outcome differences against an external benchmark would be vulnerable to differences in participants, care, assessment, and follow-up. The registry record does not report a detailed statistical analysis plan, sample-size justification, interim analysis approach, or multiplicity strategy.

The record also does not describe how missing response assessments were handled or name the analysis population used for the primary endpoint. Although it lists secondary outcomes, results for those outcomes are not reported in the details used. The available safety summary does not give causes or timing for the 12 deaths, or establish event attribution. These limitations concern what can be inferred from the registry record; they do not establish what occurred in unreported analyses.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma — NCT03264131.
• Registry record last updated 2026-07-29; status last verified 2026-06.
• Results first posted 2025-02-10.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

The registry record describes NCT03264131, titled “BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma,” as a completed, open-label, multicenter, single-arm Phase 2 pilot study sponsored by UNC Lineberger Comprehensive Cancer Center. Enrollment is listed as 16. The start date is 2018-10-11 and the primary completion date is 2023-12-15.

The study intervention combines brentuximab vedotin with cyclophosphamide, doxorubicin, etoposide, and prednisone. The primary endpoint is the count of participants with complete response after 2-6 cycles, assessed at 18 weeks using the Lugano criteria. The primary response result and its statistical uncertainty are not reported in the registry record details.

The adverse-event summary lists 7 participants with serious adverse events and 9 with other adverse events, each among 16 at risk, as well as 12 deaths. The record lists secondary outcomes related to response, survival, duration of response, and adverse events. Detailed analysis methods, missing-data handling, and multiplicity procedures are not reported in the registry record.